JP7410018B2 - A群レンサ球菌に対する免疫原性ペプチド - Google Patents
A群レンサ球菌に対する免疫原性ペプチド Download PDFInfo
- Publication number
- JP7410018B2 JP7410018B2 JP2020511429A JP2020511429A JP7410018B2 JP 7410018 B2 JP7410018 B2 JP 7410018B2 JP 2020511429 A JP2020511429 A JP 2020511429A JP 2020511429 A JP2020511429 A JP 2020511429A JP 7410018 B2 JP7410018 B2 JP 7410018B2
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- seq
- protein
- spycep
- peptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2019439 | 2017-08-23 | ||
| NL2019439 | 2017-08-23 | ||
| PCT/AU2018/050893 WO2019036761A1 (en) | 2017-08-23 | 2018-08-22 | IMMUNOGENIC PEPTIDE DIRECTED AGAINST GROUP A STREPTOCOCCUS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021505525A JP2021505525A (ja) | 2021-02-18 |
| JP2021505525A5 JP2021505525A5 (https=) | 2021-09-30 |
| JP7410018B2 true JP7410018B2 (ja) | 2024-01-09 |
Family
ID=60515757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511429A Active JP7410018B2 (ja) | 2017-08-23 | 2018-08-22 | A群レンサ球菌に対する免疫原性ペプチド |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11732033B2 (https=) |
| EP (1) | EP3672628A4 (https=) |
| JP (1) | JP7410018B2 (https=) |
| KR (1) | KR102893870B1 (https=) |
| CN (1) | CN111344007A (https=) |
| AU (1) | AU2018322485B2 (https=) |
| BR (1) | BR112020003734A2 (https=) |
| CA (1) | CA3073580A1 (https=) |
| MX (1) | MX2020002014A (https=) |
| SG (1) | SG11202001557PA (https=) |
| WO (1) | WO2019036761A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX392514B (es) * | 2014-04-15 | 2025-03-24 | Univ Griffith | Vacuna para estreptococo del grupo a. |
| NL2023863B1 (en) | 2019-09-20 | 2021-05-25 | Univ Griffith | Protein particles and uses thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090162369A1 (en) | 2007-12-12 | 2009-06-25 | Katin Helena Threse Nordstrom | Synthetic chimeric peptides |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090010929A1 (en) * | 2006-12-04 | 2009-01-08 | Good Michael F | Therapeutic Antibodies, Antibody Fragments and Antibody Conjugates |
| SG10201605512WA (en) * | 2011-07-06 | 2016-09-29 | Novartis Ag | Oil-in-water emulsions that contain nucleic acids |
| MX392514B (es) * | 2014-04-15 | 2025-03-24 | Univ Griffith | Vacuna para estreptococo del grupo a. |
| CN106606775A (zh) * | 2015-10-27 | 2017-05-03 | 格里菲斯大学 | 脂质体a群链球菌疫苗 |
-
2018
- 2018-08-22 WO PCT/AU2018/050893 patent/WO2019036761A1/en not_active Ceased
- 2018-08-22 CN CN201880068348.0A patent/CN111344007A/zh active Pending
- 2018-08-22 AU AU2018322485A patent/AU2018322485B2/en active Active
- 2018-08-22 BR BR112020003734-6A patent/BR112020003734A2/pt unknown
- 2018-08-22 JP JP2020511429A patent/JP7410018B2/ja active Active
- 2018-08-22 CA CA3073580A patent/CA3073580A1/en active Pending
- 2018-08-22 EP EP18847435.7A patent/EP3672628A4/en active Pending
- 2018-08-22 MX MX2020002014A patent/MX2020002014A/es unknown
- 2018-08-22 SG SG11202001557PA patent/SG11202001557PA/en unknown
- 2018-08-22 KR KR1020207008215A patent/KR102893870B1/ko active Active
- 2018-08-22 US US16/640,819 patent/US11732033B2/en active Active
-
2023
- 2023-05-24 US US18/201,595 patent/US12383630B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090162369A1 (en) | 2007-12-12 | 2009-06-25 | Katin Helena Threse Nordstrom | Synthetic chimeric peptides |
Non-Patent Citations (2)
| Title |
|---|
| ChemBioChem, 2006, Vol.7, pp.275-286 |
| Scientific Reports, 2016, Vol.6, Article No.39274, pp.1-11 |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2020111297A (ru) | 2021-09-23 |
| US11732033B2 (en) | 2023-08-22 |
| SG11202001557PA (en) | 2020-03-30 |
| CA3073580A1 (en) | 2019-02-28 |
| US20230382981A1 (en) | 2023-11-30 |
| EP3672628A4 (en) | 2021-06-30 |
| US12383630B2 (en) | 2025-08-12 |
| KR102893870B1 (ko) | 2025-12-02 |
| BR112020003734A2 (pt) | 2020-09-01 |
| US20210024619A1 (en) | 2021-01-28 |
| RU2020111297A3 (https=) | 2021-12-23 |
| CN111344007A (zh) | 2020-06-26 |
| EP3672628A1 (en) | 2020-07-01 |
| JP2021505525A (ja) | 2021-02-18 |
| MX2020002014A (es) | 2020-10-14 |
| KR20200046059A (ko) | 2020-05-06 |
| AU2018322485A1 (en) | 2020-03-12 |
| WO2019036761A1 (en) | 2019-02-28 |
| AU2018322485B2 (en) | 2024-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5931724B2 (ja) | StreptococcusPneumoniaeに対するワクチンおよび組成物 | |
| JP7072921B2 (ja) | A群レンサ球菌ワクチン | |
| KR20140017554A (ko) | 폐렴 구균에 대한 백신 및 조성물 | |
| US12383630B2 (en) | Immunogenic peptide against group a Streptococcus | |
| CN106279435A (zh) | 靶向VEGF与mucin1的抗肿瘤疫苗、编码基因、表达载体、表达工程菌及应用 | |
| RU2775621C2 (ru) | Иммуногенный пептид против стрептококков группы а | |
| KR20080106985A (ko) | Nmb0938 단백질을 포함하는 약학적 조성물 | |
| HK1238144B (zh) | A群链球菌疫苗 | |
| CN101443037A (zh) | 包含蛋白质nma0939的药物组合物 | |
| HK1238144A1 (en) | Group a streptococcus vaccine | |
| BRPI1103672A2 (pt) | sequÊncia de Ácido nuclÉico recombinante que codifica para os aminoÁcidos 39 a 512 da proteÍna p1 do s. mutans, proteÍna recombinante e seus usos na prevenÇço e controle da cÁrie dental | |
| HK1172254A (en) | Vaccines and compositions against streptococcus pneumoniae |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A529 Effective date: 20200420 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201113 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210106 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210823 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210823 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220623 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220704 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221004 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230130 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230501 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230718 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230828 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231127 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231221 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7410018 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |